First human trial in Singapore for COVID-19 vaccine to begin soon: Duke-NUS

Duke-NUS Medical School and clinical-stage messenger RNA medicines company Arcturus Therapeutics will be embarking on the first human trial of a COVID-19 vaccine candidate in Singapore.

They will be initiating human dosing of LUNAR-COV19 as soon as possible. 

In a press statement, Duke-NUS Medical School said its Clinical Trial Application for the COVID-19 vaccine candidate LUNAR-COV19 has been approved to proceed by the Health Sciences Authority (HSA). 

Photo courtesy: Duke-NUS
Photo courtesy: Duke-NUS

"The healthy volunteer study will evaluate several dose levels of LUNAR-COV19 in up to 108 adults, including older adults."

Professor Ooi Eng Eong, Deputy Director of the Emerging Infectious Diseases Programme at Duke-NUS, said, “Preclinical studies on LUNAR-COV19 have shown very promising findings, including the possibility that a single dose of this vaccine may be sufficient to trigger robust and durable immune responses against SARS-CoV-2."

He added, "We are very eager to start the first-in-human clinical trial here in Singapore and advance LUNAR-COV19 on its journey to becoming a potential commercial vaccine.”

LUNAR-COV19 was developed using Arcturus’ STARR technology and a unique platform developed at Duke-NUS allowing rapid screening of vaccines for potential effectiveness and safety.

Author
CtoI News Desk
CtoI News Desk – CtoI

Singapore-headquartered online media company targeting Indian Diaspora across Singapore, US, UK and Dubai. Connected to India covers developments around Indians abroad, informing, engaging and entertaining its audiences.

Comments